date,title,source
Oct-17-18,Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy,GlobeNewswire
Oct-18-18,Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimers Disease Agitation,GlobeNewswire
Nov-01-18,"Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018",GlobeNewswire
Nov-09-18,Axsome: 3Q Earnings Snapshot,Associated Press
Nov-09-18,Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update,GlobeNewswire
Nov-14-18,Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder,GlobeNewswire
Nov-19-18,Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference,GlobeNewswire
